Silihan lan utang jangka dawa perusahaan Ocean Bio (OCEA)

Ocean Biomedical, Inc. (OCEA) revenues rely on the sale of rights to innovative methods for combating fibrosis, oncology, and malaria, including partnership royalties. Production capacities are currently utilized in ongoing clinical trials. This chart illustrates the long-term debt dynamics, which stand at 0.00. However, the risk of capital fragmentation and intense pressure from major laboratories create significant challenges for business development.

This indicator captures the total volume of long-term liabilities, reflecting the actual credit burden on the balance sheet. For Ocean Biomedical, Inc. (OCEA), which delegates clinical trials to external CRO partners, this metric determines the cost of financing outsourcing. By analyzing the company's long-term debt history, an investor can see the pace of loan accumulation. The dynamics of these liabilities reveal the risk of overpaying on loans, allowing for an assessment of the overall financial stability of the capital.